Kodiak Sciences (KOD)

• Market cap: $385M
• 1 day: -6.41%
• 5 days: 6.57%
• 1 month: 95.71%
• 3 months: 67.43%
• 6 months: 7.35%
• Year to date: -15.31%
• 1 year: 153.47%
• 5 years: -84.63%
• 10 years: -28.15%
• Sector: Healthcare
• Industry: Biotechnology

About: Kodiak Sciences Inc is a biopharmaceutical company specializing in novel therapeutics to treat high-prevalence retinal diseases. The product candidate of the company is BLA, which is a novel antibody biopolymer conjugate, in treatment-naive subjects with neovascular wet AMD. The pipeline products of the company include Tarcocimab tedromer, KSI-501, and KSI-101.

Employees: 113

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

2,700% more call options, than puts

Call options by funds: $56K | Put options by funds: $2K

33% more repeat investments, than reductions

Existing positions increased: 40 | Existing positions reduced: 30

17% more first-time investments, than exits

New positions opened: 21 | Existing positions closed: 18

1.54% more ownership

Funds ownership: 79.92% [Q4 2024] → 81.46% (+1.54%) [Q1 2025]

0% more funds holding

Funds holding: 106 [Q4 2024] → 106 (+0) [Q1 2025]

71% less capital invested

Capital invested by funds: $418M [Q4 2024] → $120M (-$298M) [Q1 2025]

100% less funds holding in top 10

Funds holding in top 10: 2 [Q4 2024] → 0 (-2) [Q1 2025]